Home>>Signaling Pathways>> Metabolism>> PDE>>BI-2545

BI-2545 Sale

目录号 : GC60074

An inhibitor of autotaxin

BI-2545 Chemical Structure

Cas No.:2162961-71-7

规格 价格 库存 购买数量
5mg
¥855.00
现货
10mg
¥1,620.00
现货
25mg
¥3,375.00
现货
50mg
¥6,075.00
现货
100mg
¥10,350.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

BI-2545 is an inhibitor of autotaxin (IC50s = 2.2 and 3.4 for the human and rat enzyme, respectively).1 It is selective for autotaxin over a panel of 48 enzymes, transporters, ion channels, and receptors at 10 ?M. BI-2545 (10 mg/kg) reduces plasma lysophosphatidic acid (LPA) levels in rats.

1.Kuttruff, C.A., Ferrara, M., Bretschneider, T., et al.Discovery of BI-2545: A novel autotaxin inhibitor that significantly reduces LPA levels in vivoACS Med. Chem. Lett.8(12)1252-1257(2017)

Chemical Properties

Cas No. 2162961-71-7 SDF
Canonical SMILES O=C(N1C[C@]2([H])[C@H](CNC(C3=CC=C(NN=N4)C4=C3)=O)[C@]2([H])C1)OCC5=CC(C(F)(F)F)=CC(C(F)(F)F)=C5
分子式 C23H19F6N5O3 分子量 527.42
溶解度 DMSO: 250 mg/mL (474.01 mM) 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.896 mL 9.4801 mL 18.9602 mL
5 mM 0.3792 mL 1.896 mL 3.792 mL
10 mM 0.1896 mL 0.948 mL 1.896 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo

ACS Med Chem Lett 2017 Nov 8;8(12):1252-1257.PMID:29259743DOI:PMC5733304

In an effort to find new therapeutic interventions addressing the unmet medical need of patients with idiopathic pulmonary fibrosis, we initiated a program to identify new autotaxin (ATX) inhibitors. Starting from a recently published compound (PF-8380), we identified several highly potent ATX inhibitors with improved pharmacokinetic and safety profiles. Further optimization efforts resulted in the identification of a single-digit nanomolar lead compound (BI-2545) that shows substantial lowering of LPA in vivo and is therefore considered a valuable tool for further studies.